Tovoli F, Granito A, De Lorenzo S, Bolondi L
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Drugs Today (Barc). 2018 Jan;54(1):5-13. doi: 10.1358/dot.2018.54.1.2736667.
Hepatocellular carcinoma (HCC) is a worldwide problem, with a high prevalence in nonindustrialized countries and a rising incidence in industrialized countries as well. Its close association with chronic liver diseases and liver cirrhosis represents a significant challenge in its treatment. A front-line systemic treatment for unresectable cases of HCC (sorafenib) was identified only in 2007. Following a decade of failed clinical trials with a wide range of drugs for second-line treatment, regorafenib proved its efficacy as a second-line treatment in 2016, when the randomized, placebo-controlled, phase III RESORCE trial demonstrated a meaningful increase in overall survival in the regorafenib treatment arm compared with the placebo arm (10.6 vs. 7.8 months). In this monograph we review the main preclinical and clinical findings in the trials assessing regorafenib for the treatment of HCC patients.
肝细胞癌（HCC）是一个全球性问题，在非工业化国家发病率很高，在工业化国家发病率也呈上升趋势。它与慢性肝病和肝硬化的密切关联给其治疗带来了重大挑战。直到2007年才确定了一种用于不可切除HCC病例的一线全身治疗药物（索拉非尼）。在经历了十年使用多种药物进行二线治疗的临床试验失败后，瑞戈非尼在2016年证明了其作为二线治疗药物的疗效，当时随机、安慰剂对照的III期RESORCE试验表明，与安慰剂组相比，瑞戈非尼治疗组的总生存期有显著延长（10.6个月对7.8个月）。在本专著中，我们回顾了评估瑞戈非尼治疗HCC患者的试验中的主要临床前和临床研究结果。
